For the millions of cancer patients who lose dangerous amounts of muscle mass during treatment, cachexia represents one of oncology's most intractable problems — reducing chemotherapy tolerance, quality of life, and survival without a single approved therapy. A compound already circulating in the human bloodstream may change that calculus.
Unacylated ghrelin (UnAG) — the predominant, non-hunger-signaling form of the hormone ghrelin — demonstrated striking protective effects in a Lewis lung carcinoma mouse model. Over four weeks, tumor-bearing mice treated with UnAG retained approximately 50% more lower-limb muscle mass and roughly 70% of contractile force compared to untreated tumor-bearing controls. The mechanism appears multilayered: UnAG enhanced mitochondrial oxygen consumption, suppressed reactive oxygen species production, maintained mitochondrial DNA copy number, and reduced mutation frequency in that mitochondrial genome. Critically, it also normalized neuromuscular junction disruption and downregulated the protein-degradation pathways — likely ubiquitin-proteasome and autophagy-lysosome cascades — that are hallmarks of cachectic muscle wasting.
What makes this finding particularly compelling is that UnAG works through pathways largely distinct from acylated ghrelin's appetite-stimulating route, potentially sidestepping the appetite dysregulation and cardiovascular concerns that have complicated ghrelin-based therapies. The dual targeting of mitochondrial bioenergetics and neuromuscular integrity is mechanistically novel; most cachexia research focuses on either proteolysis or inflammation, rarely both simultaneously. That said, the limitations here are substantial. This is a single preclinical study in male mice using a subcutaneous tumor model, which notoriously fails to recapitulate the full complexity of human cancer cachexia. Human trials would need to establish safe dosing, delivery routes, and efficacy across cancer types and sexes. Overall, this qualifies as a genuinely promising mechanistic advance — not yet practice-changing, but strong enough to justify accelerated translational work.